Eprex 4000 is a medication that helps your bone marrow produce more red blood cells. It is used to treat a type of anemia caused by kidney disease.
1. What is Eprex 4000?
Eprex 4000 belongs to a class of drugs called erythropoiesis-stimulating agents, primarily used to treat anemia (low hemoglobin in the blood) due to chronic kidney disease and chemotherapy-induced anemia (due to cancer treatment). Anemia is a condition characterized by low hemoglobin levels and red blood cells (RBCs) in the blood. Patients with chronic kidney disease (CKD) develop anemia gradually, which worsens as the disease progresses. Furthermore, cancer treatments, including chemotherapy and radiation, can cause anemia in cancer patients.
Eprex 4000 contains 'Recombinant human erythropoietin alfa'. Eprex 4000 works by stimulating the bone marrow (the soft tissue inside bones that produces red blood cells) to produce more red blood cells. Eprex 4000 is very similar to a natural substance in the body called erythropoietin (a hormone produced by the kidneys that stimulates RBC production), preventing anemia (a lack of hemoglobin and RBCs in the blood).
2. Uses of the Drug
Eprex 4000 is indicated for the treatment of symptomatic anemia related to chronic renal failure (CRF):
- In adults and children aged 1 to 18 years on hemodialysis and adults on peritoneal dialysis.
- In adults with renal failure who are not on dialysis to treat severe anemia of renal origin with clinical symptoms.
Eprex 4000 is indicated in adults undergoing chemotherapy for solid tumors, malignant lymphoma, or multiple myeloma, and who are at risk of requiring blood transfusions based on the overall health status (e.g., pre-existing anemia before starting chemotherapy) to treat anemia and reduce the need for blood transfusions.
Eprex 4000 is indicated for adults in a pre-operative program to increase autologous blood production. Treatment should only be given to patients with moderate anemia (hemoglobin levels ranging from 10 to 13 g/dL [6.2 to 8.1 mmol/L], without iron deficiency) when blood-saving procedures are not available or sufficient for major elective surgeries requiring large blood loss (4 units of blood or more for females, 5 units or more for males). Eprex 4000 is indicated for adults with no iron deficiency before major elective orthopedic surgeries who are at high risk for complications from blood transfusions to reduce exposure to allogeneic blood transfusion. Use should be limited to patients with moderate anemia (e.g., hemoglobin levels between 10 and 13 g/dL), who do not have an available autologous blood program and who are expected to lose moderate amounts of blood (900 to 1,800 mL).
Eprex 4000 is indicated for the treatment of symptomatic anemia (hemoglobin ≤10 g/dL) in adults with low to intermediate-risk primary myelodysplastic syndrome (MDS) with low serum erythropoietin levels.
3. Dosage and Administration
Eprex 4000 is only available as an injection, administered subcutaneously (under the skin) or intravenously (into the vein). Those who receive the drug subcutaneously may be taught to administer the medication themselves. Be sure to understand exactly how to administer the injection, as instructed by your doctor or nurse. Those who require intravenous administration will need the medication given by a doctor or nurse.
- For children with chronic renal failure, the starting dose for anemia is 50 units (IU) per kg of body weight, administered 3 times a week.
- For adults with chronic kidney failure, the starting dose for anemia is 50 to 100 units per kg of body weight, injected three times a week.
- For adults with HIV-related anemia, the usual starting dose is 100 units per kg of body weight, injected 3 times a week.
- For chemotherapy-induced anemia, the starting dose is 150 units per kg of body weight, injected subcutaneously 3 times a week. Alternatively, epoetin alfa can be injected subcutaneously once a week at a dose of 40,000 units. Your doctor may need to adjust the dose based on your body's response to the medication. Dose adjustments are typically made based on blood tests and are not performed more frequently than every 4 weeks. While you are being treated with epoetin alfa, your doctor may want you to supplement with iron to help the medication work effectively.
4. Side effects
Some side effects may occur while using the medication. If you experience the following, consult your doctor immediately:
- Clotting at the site of vascular access (for those on dialysis)
- Swelling (face, fingers, ankles, feet, or lower legs)
- Flu-like symptoms (e.g., dizziness, drowsiness, fever, headache, muscle and joint pain)
- Increased headaches
- Increased or decreased blood pressure, dizziness, or fainting
- Muscle aches
- Difficulty breathing with mild exertion
- Discontinue the medication and seek immediate medical care if any of the following occur:
- Chest pain
- Seizures
- Signs of an allergic reaction (such as rash or hives, difficulty breathing, sweating, abnormal heart rhythms, or low blood pressure)
- Signs of a blood clot (pain or swelling in the legs, worsening shortness of breath, coughing up blood)
- Signs of a serious skin reaction (such as rash, redness, blistering of the lips, eyes, or mouth, peeling skin, fever, or joint pain)
- Symptoms of a stroke (confusion, severe headache, sudden weakness, dizziness, difficulty speaking, or vision problems)
5. Precautionary Measures
Before you start using this medication, make sure to inform your doctor about any medical conditions or allergies you have, any medications you are taking, whether you are pregnant or breastfeeding, and any other important health information. These factors can affect how you should use this medication.
5.1 Blood Clots
In clinical trials, patients with cancer and chronic kidney disease treated with epoetin alfa to raise hemoglobin levels above normal have a higher risk of developing blood clots, which in some cases may be fatal. Your doctor will closely monitor your hemoglobin levels through blood tests during treatment.
If you experience symptoms such as sharp pain and swelling in your legs, or difficulty breathing, contact your doctor immediately.
5.2 Cancer
Epoetin alfa is used to treat anemia caused by chemotherapy for non-myeloid cancers. It is not used to treat anemia caused by cancer itself. If you have cancer and your hemoglobin is maintained at too high a level, your cancer may grow faster, or you may increase your risk of heart attack or stroke.
5.3 Cardiovascular Disease
This medication can affect blood pressure and may contribute to heart disease symptoms. If you have high blood pressure, heart disease such as heart failure, angina, or a previous heart attack, discuss with your doctor how this medication might affect your health, how your health might affect the dose and effectiveness of this medication, and whether special monitoring is needed. If you are taking blood pressure medications to control blood pressure, it is important to continue taking them regularly while using epoetin alfa. Your doctor will monitor your hemoglobin (the protein in red blood cells that carries oxygen) until the appropriate dose of epoetin alfa is determined.
5.4 Gout
This medication may cause symptoms of gout. If you have gout or a history of gout, discuss with your doctor how this medication might affect your condition.
5.5 Kidney Disease
This medication can be used by individuals with chronic kidney disease who are on dialysis and those who are not on dialysis. The dosage may differ for each group.
5.6 Medical Conditions
Be sure to inform your doctor if you have any of the following medical conditions, as they may affect the effectiveness of this medication:
- Folic acid, iron, or vitamin B12 deficiency
- Excess aluminum in the blood
- Infection
- Inflammatory disorders
- Cancer
- Bone problems
5.7 Porphyrin Metabolic Disorders
If you have a history of porphyrin metabolic disorders (a metabolic disorder), discuss with your doctor how this medication might affect your condition, how your health could impact the dose and effectiveness of the medication, and whether any special monitoring is required.
5.8 Pure Red Cell Aplasia (PRCA)
Cases of pure red cell aplasia (PRCA) have been reported in individuals treated with epoetin alfa. PRCA is a condition where the bone marrow stops producing red blood cells, leading to severe anemia. People who develop PRCA may experience new or worsening fatigue or shortness of breath. If you experience these symptoms, contact your doctor as soon as possible. Do not stop your medication without consulting your doctor first.
5.9 Seizures
This medication may contribute to seizures, although the relationship between epoetin alfa and seizures is unclear. If you have seizures or a history of seizures, discuss with your doctor how this medication may affect your condition.
6. Drug interactions
Drug-drug interactions: This medication may interact with medications used after kidney transplants (e.g., cyclosporine), cancer and anemia treatments (e.g., lenalidomide), medications for skin diseases and cancer (e.g., thalidomide), and anti-cancer drugs (e.g., pomalidomide).
Drug-disease interactions: This medication should not be used for patients with high blood pressure or joint disorders.
7. Additional Notes
- Avoid making any dietary changes without consulting your doctor.
- Your doctor may perform regular blood tests to check your blood cell count, hemoglobin levels, and electrolytes such as potassium.
- Eat foods rich in iron, vitamin B12, and folic acid, such as leafy greens, fish, eggs, and liver.
- Engage in light to moderate exercise.
- The medication may stop working well after some time due to the body potentially developing antibodies. Inform your doctor immediately if symptoms of anemia return (increased fatigue, low energy, pale skin, shortness of breath).
To arrange an appointment, please call HOTLINE or make your reservation directly HERE. You may also download the MyVinmec app to schedule appointments faster and manage your reservations more conveniently.
